The efficacy of furosemide in reducing methotrexate toxicity in patients suffering from Acute lymphoblastic leukemia
Phase 2
- Conditions
- Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
- Registration Number
- CTRI/2024/02/062267
- Lead Sponsor
- All India Institute of medical sciencesPatna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Children diagnosed to have acute lymphoblastic leukemia on high dose methotrexate therapy.
Exclusion Criteria
children with chronic kidney disease,Chronic liver disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum methotrexate levelsTimepoint: 48 hours after starting high dose methotrexate Therapy.
- Secondary Outcome Measures
Name Time Method hemoglobin levels,ANC levels ,Liver enzymes, urea and creatinineTimepoint: 48 hrs